Quarterly Results Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Mar'24
Net Sales
1,110.33
1,068.76
1,062.21
1,011.17
958.43
951.66
1,090.97
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
1,110.33
1,068.76
1,062.21
1,011.17
958.43
951.66
1,090.97
Raw Material Cost
276.14
284.01
282.22
278.13
267.34
295.80
328.91
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
4.88
4.97
4.35
4.01
4.34
3.88
3.95
Selling and Distribution Expenses
486.13
504.06
468.07
439.24
412.39
425.47
440.33
Other Expenses
12.27
11.09
9.25
10.04
8.95
8.17
9.45
Total Expenditure (Excl Depreciation)
889.90
903.95
847.16
821.80
773.61
806.87
867.71
Operating Profit (PBDIT) excl Other Income
220.39999999999998
164.8
215
189.4
184.8
144.8
223.29999999999998
Other Income
35.01
35.71
33.72
50.70
20.29
39.06
35.87
Operating Profit (PBDIT)
239.31
297.74
342.23
153.92
286.35
268.94
339.06
Interest
4.88
4.97
4.35
4.01
4.34
3.88
3.95
Exceptional Items
1.94
2.91
2.82
6.60
2.53
3.91
1.47
Gross Profit (PBDT)
834.19
784.75
779.99
733.04
691.09
655.86
762.06
Depreciation
0.00
108.56
108.56
105.14
105.14
99.34
99.34
Profit Before Tax
236.37
187.13
232.15
51.37
179.41
169.64
237.24
Tax
18.06
16.14
25.10
-34.84
9.65
19.93
32.62
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
215.63
164.75
200.33
91.85
165.62
143.83
200.27
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
215.63
164.75
200.33
91.85
165.62
143.83
200.27
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.40
7.76
2.53
1.21
2.17
2.36
-2.15
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
216.02
172.51
202.86
93.07
167.79
146.19
198.11
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
8,772.55
8,538.96
8,918.36
8,712.15
8,606.63
7,834.29
8,226.39
Earnings per share (EPS)
0.19
0.15
0.18
0.08
0.15
0.13
0.18
Diluted Earnings per share
0.19
0.15
0.18
0.08
0.15
0.13
0.18
Operating Profit Margin (Excl OI)
18.4%
14.36%
18.82%
-0.19%
16.79%
13.72%
18.69%
Gross Profit Margin
21.29%
27.67%
32.08%
15.48%
29.69%
28.26%
30.85%
PAT Margin
19.42%
15.41%
18.86%
9.08%
17.28%
15.11%
18.36%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Sep 2025 is 15.85% vs 24.15% in Sep 2024
Consolidate Net Profit
YoY Growth in quarter ended Sep 2025 is 28.72% vs 18.67% in Sep 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Sep 2025 is -23.22% vs 16.92% in Sep 2024
Interest
YoY Growth in quarter ended Sep 2025 is 13.95% vs -14.00% in Sep 2024
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024
Compare Quarterly Results Of Shenzhen Salubris Pharmaceuticals Co., Ltd. With
Figures in Million
Consolidate Quarterly Results
Change(CNY)
Change(%)
Net Sales
1,110.33
0
1,110.33
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,110.33
0
1,110.33
Raw Material Cost
276.14
0
276.14
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
4.88
0
4.88
Selling and Distribution Expenses
486.13
0
486.13
Other Expenses
12.27
0.00
12.27
Total Expenditure (Excl Depreciation)
889.90
0
889.90
Operating Profit (PBDIT) excl Other Income
220.43
0.00
220.43
Other Income
35.01
0
35.01
Operating Profit (PBDIT)
239.31
0
239.31
Interest
4.88
0
4.88
Exceptional Items
1.94
0
1.94
Gross Profit (PBDT)
834.19
0
834.19
Depreciation
0.00
0
0.00
Profit Before Tax
236.37
0
236.37
Tax
18.06
0
18.06
Provisions and contingencies
0
0
0.00
Profit After Tax
215.63
0
215.63
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
215.63
0
215.63
Share in Profit of Associates
0
0
0.00
Minority Interest
0.40
0
0.40
Other related items
0.00
0.00
0.00
Consolidated Net Profit
216.02
0
216.02
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
8,772.55
0
8,772.55
Earnings per share (EPS)
0.19
0
0.19
Diluted Earnings per share
0.19
0
0.19
Operating Profit Margin (Excl OI)
18.40%
0%
0.00
18.40%
Gross Profit Margin
21.29%
0%
0.00
21.29%
PAT Margin
19.42%
0%
0.00
19.42%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 111.03 Million
in Sep 2025Figures in Million
QoQ Growth in quarter ended Sep 2025 is 3.88% vs 0.62% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 15.85% vs 24.15% in Sep 2024
Quarterly - Consolidate Net Profit
Consolidate Net Profit 21.60 Million
in Sep 2025Figures in Million
QoQ Growth in quarter ended Sep 2025 is 25.22% vs -14.98% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 28.72% vs 18.67% in Sep 2024
Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 20.43 Million
in Sep 2025Figures in Million
QoQ Growth in quarter ended Sep 2025 is -22.02% vs -15.07% in Jun 2025
YoY Growth in quarter ended Sep 2025 is -23.22% vs 16.92% in Sep 2024
Quarterly - Interest
Interest 0.49 Million
in Sep 2025Figures in Million
QoQ Growth in quarter ended Sep 2025 is -2.00% vs 16.28% in Jun 2025
YoY Growth in quarter ended Sep 2025 is 13.95% vs -14.00% in Sep 2024
Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 18.40%
in Sep 2025Figures in %
QoQ Growth in quarter ended Sep 2025 has improved from Jun 2025
YoY Growth in quarter ended Sep 2025 has improved from Sep 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
